Biocon is currently trading at RS 403.50, up by 3.35 points or 0.84% from its previous closing of RS 400.15 on the BSE.

The stock opened at RS 404.60 and has touched an intraday high and low of RS 407.40 and RS 402.40 respectively. A total of 97,011 shares have been traded so far.

The BSE group ‘A’ stock with face value RS 5 recorded a 52-week high of RS 424.95 on 18-Nov-2025 and a 52-week low of RS 290.80 on 03-Mar-2025.

In the past week, the stock has traded between a high of RS 407.40 and a low of RS 390.25. The company’s current market capitalization stands at RS 53,893.00 crore.

Shareholding data shows promoters hold 54.45%, while Institutions and Non-Institutions hold 28.71% and 16.83% respectively.

Biocon’s subsidiary Biocon Biologics has signed a settlement agreement with Amgen Inc., enabling commercialization of its Denosumab biosimilars in Europe and the rest of the world. The company can begin commercializing its products Vevzuo and Evfraxy in Europe starting December 2, 2025. Other terms of the agreement remain confidential.

The European Commission granted approval for Vevzuo and Evfraxy in July 2025, and Biocon has already secured entry for its Denosumab biosimilars Bosaya and Aukelso in the United States.

Biocon is recognized as India’s largest and Asia’s leading biotechnology company, focused on biopharmaceuticals and research services, delivering affordable treatment solutions for chronic diseases globally.